The aim of this study was to determine semiquantitatively megakaryocyte glycogen and related parameters as an aid to diagnosis and treatment of idiopathic thrombocytopenic purpura (ITP). The tests were applied to 100 patients diagnosed with ITP from various hospitals and clinics, and 100 apparently healthy subjects who was gave informed consent according to the Declaration of Helsinki. Investigating the presence of glycogen in megakaryocytes of bone marrow smears using the method of peryodic acid-Schiff and complementary tests of hemostasis: platelets by the method of Rees-Ecker, mean platelet volume (MPV) using the automatic analyzer Sysmex XE-2100, prothrombin time, partial thromboplastin time (PTT), bleeding time, fibrinogen, hemoglobin and red blood cell count by the usual methods. We conclude that patients with ITP megakaryocyte glycogen had decreased (100%), alterations in some coa...

The aim of this study was to determine semiquantitatively megakaryocyte glycogen and related parameters as an aid to diagnosis and treatment of idiopathic thrombocytopenic purpura (ITP). The tests were applied to 100 patients diagnosed with ITP from various hospitals and clinics, and 100 apparently healthy subjects who was gave informed consent according to the Declaration of Helsinki. Investigating the presence of glycogen in megakaryocytes of bone marrow smears using the method of peryodic acid-Schiff and complementary tests of hemostasis: platelets by the method of Rees-Ecker, mean platelet volume (MPV) using the automatic analyzer Sysmex XE-2100, prothrombin time, partial thromboplastin time (PTT), bleeding time, fibrinogen, hemoglobin and red blood cell count by the usual methods. We conclude that patients with ITP megakaryocyte glycogen had decreased (100%), alterations in some coa...

En este documento se plasma la evaluación de la eficacia y seguridad del uso del producto farmacéutico ceftolozano/tazobactam en pacientes adultos con enfermedad renal crónica e infección del tracto urinario por pseudomonas XDR con sensibilidad demostrada a ceftolozano/tazobactam; cuyos resultados sustentaron la no aprobación del uso de esta tecnología sanitaria en EsSalud.

La enfermedad renal crónica (ERC) es un problema de Salud Pública con un alto costo económico para los sistemas de salud. Su prevalencia mundial es de 13,4% y según Francis se estima que en el Perú alcanza al 16.8% de la población. En nuestro país no existen estudios de prevalencia con inferencia nacional, las cifras disponibles se basan en estimados referenciales, así se considera que afecta a más de 2 millones de adultos peruanos y según un estudio realizado en EsSalud a 28.2% de pacientes con factores de riesgo (diabéticos, hipertensos y mayores de 55 años)